Long‑term effects of COVID‑19 in sickle cell disease: A case report

Alberca,Ricardo Wesley; Orfali,Raquel Leão; Rigato,Paula Ordonhez; Duarte,Alberto José Da Silva; Aoki,Valeria; Sato,Maria Notomi

doi:10.3892/wasj.2021.117

Long‑term effects of COVID‑19 in sickle cell disease: A case report

Authors:
- Ricardo Wesley Alberca
- Raquel Leão Orfali
- Paula Ordonhez Rigato
- Alberto José Da Silva Duarte
- Valeria Aoki
- Maria Notomi Sato
View Affiliations

Affiliations: Laboratory of Dermatology and Immunodeficiencies, LIM‑56, Department of Dermatology, School of Medicine and Institute of Tropical Medicine of São Paulo, University of São Paulo, São Paulo, SP 05403‑000, Brazil, Immunology Center, Adolfo Lutz Institute, São Paulo, SP 01246‑000, Brazil
Published online on: July 19, 2021 https://doi.org/10.3892/wasj.2021.117
Article Number: 46
Copyright: © Alberca et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) infection can generate a respiratory and systemic disease known as coronavirus disease 2019 (COVID‑19). To date, at least to the best of our knowledge, only a limited number of studies have identified SARS‑CoV‑2 infection in patients with sickle cell disease (SCD). Due to the lack of knowledge of the long‑term effects of COVID‑19, the present study presents the hematological alterations in a patient with SCD during hospitalization due to COVID‑19 and for up to 180 days following SARS‑CoV‑2 clearance and hospital discharge. The present study describes the case of a patient with SCD who was diagnosed with moderate COVID‑19 infection, without the need for invasive mechanical ventilation. Following SARS‑CoV‑2 clearance, long‑term (6 months) follow‑up identified an increase in the reticulocyte frequency, creatinine and D‑dimer levels. On the whole, the present study manuscript presents the case of a patient with moderate COVID‑19 infection with long‑term laboratory alterations at even 6 months following SARS‑CoV‑2 clearance. Further investigations are required however, to focus on the long‑term evaluations in patients who have recovered from COVID‑19, in order to fully determine the extension of possible sequelae.

View Figures

View References

1	Tsai SC, Lu CC, Bau DT, Chiu YJ, Yen YT, Hsu YM, Fu CW, Kuo SC, Lo YS, Chiu HY, et al: Approaches towards fighting the COVID-19 pandemic (review). Int J Mol Med. 47:3–22. 2021.PubMed/NCBI View Article : Google Scholar
2	Pandey V and Singh A, Siddiqui S, Raikwar A, Gond AK, Ali S, Yadav M, Datta A and Singh A: COVID-19: An update of current knowledge (Review). World Acad Sci J. 3(1)2021.
3	Chen C, Guan Y, Wei J, Zhou Y, Yao W, Li X and Hei Z: Restricting activity and earlier oxygen supplementation may reduce adverse outcomes in patients with COVID-19 (Review). World Acad Sci J. 3(1)2021.
4	Alberca RW, Lima JC, de Oliveira EA, Gozzi-Silva SC, Ramos YÁ, Andrade MM, Beserra DR, Oliveira LM, Branco AC, Pietrobon AJ, et al: COVID-19 disease course in former smokers, smokers and COPD patients. Front Physiol. 11(637627)2021.PubMed/NCBI View Article : Google Scholar
5	Leung JM, Yang CX, Tam A, Shaipanich T, Hackett TL, Singhera GK, Dorscheid DR and Sin DD: ACE-2 expression in the small airway epithelia of smokers and COPD patients: Implications for COVID-19. Eur Respir J. 55(2000688)2020.PubMed/NCBI View Article : Google Scholar
6	Vardavas CI and Nikitara K: COVID-19 and smoking: A systematic review of the evidence. Tob Induc Dis. 18(20)2020.PubMed/NCBI View Article : Google Scholar
7	Alberca RW, Rigato PO, Ramos YÁL, Teixeira FME, Castelo Branco ACC, Fernandes IG, Pietrobon AJ, Duarte AJDS, Aoki V, Orfali RL and Sato MN: Clinical characteristics and survival analysis in frequent alcohol consumers with COVID-19. Front Nutr. 8(689296)2021.PubMed/NCBI View Article : Google Scholar
8	Lai CC, Wang CY and Hsueh PR: Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents? J Microbiol Immunol Infect. 53:505–512. 2020.PubMed/NCBI View Article : Google Scholar
9	Alberca R, Aoki V and Sato M: COVID-19 and HIV: Case reports of 2 co-infected patients with different disease courses. World Acad Sci J. 3(4)2020.
10	Barron E, Bakhai C, Kar P, Weaver A, Bradley D, Ismail H, Knighton P, Holman N, Khunti K, Sattar N, et al: Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: A whole-population study. Lancet Diabetes Endocrinol. 8:813–822. 2020.PubMed/NCBI View Article : Google Scholar
11	Codo AC, Davanzo GG, Monteiro LB, de Souza GF, Muraro SP, Virgilio-da-Silva JV, Prodonoff JS, Carregari VC, de Biagi Junior CAO, Crunfli F, et al: Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1α/glycolysis-dependent axis. Cell Metab. 32:437–446.e5. 2020.PubMed/NCBI View Article : Google Scholar
12	Alberca RW, Oliveira LM, Branco AC, Pereira NZ and Sato MN: Obesity as a risk factor for COVID-19: An overview. Crit Rev Food Sci Nutr. 61:2262–2276. 2021.PubMed/NCBI View Article : Google Scholar
13	Liu K, Chen Y, Lin R and Han K: Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. J Infect. 80:e14–e18. 2020.PubMed/NCBI View Article : Google Scholar
14	Perrotta F, Corbi G, Mazzeo G, Boccia M, Aronne L, D'Agnano V, Komici K, Mazzarella G, Parrella R and Bianco A: COVID-19 and the elderly: Insights into pathogenesis and clinical decision-making. Aging Clin Exp Res. 32:1599–1608. 2020.PubMed/NCBI View Article : Google Scholar
15	Minniti CP, Zaidi AU, Nouraie M, Manwani D, Crouch GD, Crouch AS, Callaghan MU, Carpenter S, Jacobs C, Han J, et al: Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection. Blood Adv. 5:207–215. 2021.PubMed/NCBI View Article : Google Scholar
16	Arlet JB, de Luna G, Khimoud D, Odièvre MH, de Montalembert M, Joseph L, Chantalat-Auger C, Flamarion E, Bartolucci P, Lionnet F, et al: Prognosis of patients with sickle cell disease and COVID-19: A French experience. Lancet Haematol. 7:e632–e634. 2020.PubMed/NCBI View Article : Google Scholar
17	Ware RE, de Montalembert M, Tshilolo L and Abboud MR: Sickle cell disease. Lancet. 390:311–323. 2017.PubMed/NCBI View Article : Google Scholar
18	Yue L, Lin M, Chen JT, Zhan XF, Zhong DS, Monte-Nguba SM, Liu PF, Pan XF, Huang JH, Wang X, et al: Rapid screening for sickle cell disease by polymerase chain reaction-high resolution melting analysis. Mol Med Rep. 9:2479–2484. 2014.PubMed/NCBI View Article : Google Scholar
19	Zhang X, Li C and Li Q: Magnetic resonance imaging in pediatric sickle cell anemia. Exp Ther Med. 12:555–558. 2016.PubMed/NCBI View Article : Google Scholar
20	Berzuini A, Bianco C, Migliorini AC, Maggioni M, Valenti L and Prati D: Red blood cell morphology in patients with COVID-19-related anaemia. Blood Transfus. 19:34–36. 2021.PubMed/NCBI View Article : Google Scholar
21	Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, Psaltopoulou T, Gerotziafas G and Dimopoulos MA: Hematological findings and complications of COVID-19. Am J Hematol. 95:834–847. 2020.PubMed/NCBI View Article : Google Scholar
22	Ye J, Jiao Y, Zhang Y, Li Z, Zeng X, Deng H and Yang M: Hematological changes in patients with COVID-19 (review). Mol Med Rep. 22:4485–4491. 2020.PubMed/NCBI View Article : Google Scholar
23	Alberca RW, Yendo TM, Leuzzi Ramos YÁ, Fernandes IG, Oliveira LM, Teixeira FM, Beserra DR, de Oliveira EA, Gozzi-Silva SC, Andrade MM, et al: Case Report: COVID-19 and chagas disease in two coinfected patients. Am J Trop Med Hyg. 103:2353–2356. 2020.PubMed/NCBI View Article : Google Scholar
24	Netea MG, Giamarellos-Bourboulis EJ, Domínguez-Andrés J, Curtis N, van Crevel R, van de Veerdonk FL and Bonten M: Trained immunity: A tool for reducing susceptibility to and the severity of SARS-CoV-2 infection. Cell. 181:969–977. 2020.PubMed/NCBI View Article : Google Scholar
25	Vasarmidi E, Tsitoura E, Spandidos D, Tzanakis N and Antoniou K: Pulmonary fibrosis in the aftermath of the Covid-19 era (review). Exp Ther Med. 20:2557–2560. 2020.PubMed/NCBI View Article : Google Scholar
26	Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink S, Schneider J, Schmidt ML, et al: Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 25(2000045)2020.PubMed/NCBI View Article : Google Scholar
27	Singh AK, Jena A, Kumar-M P, Sharma V and Sebastian S: Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: A systematic review and meta-analysis. United European Gastroenterol J. 9:159–176. 2021.PubMed/NCBI View Article : Google Scholar
28	Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA and Gao YD: Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 75:1730–1741. 2020.PubMed/NCBI View Article : Google Scholar
29	Panepintoa JA, Brandow A, Mucalo L, Yusuf F, Singh A, Taylor B, Woods K, Payne AB, Peacock G and Schieve LA: Coronavirus disease among persons with sickle cell disease, United States, March 20-May 21, 2020. Emerg Infect Dis. 26:2473–2476. 2020.PubMed/NCBI View Article : Google Scholar
30	Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 395:497–506. 2020.PubMed/NCBI View Article : Google Scholar
31	Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, Liu L, Shan H, Lei C, Hui DSC, et al: Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 382:1708–1720. 2020.PubMed/NCBI View Article : Google Scholar
32	Abdulrahman A, Wael M, AlAmmadi F, Almosawi Z, Alsherooqi R, Abduljalil M, Kumar N and AlQahtani M: Is sickle cell disease a risk factor for severe COVID-19 outcomes in hospitalized patients? A multicenter national retrospective cohort study. eJHaem. 2:167–174. 2021.PubMed/NCBI View Article : Google Scholar
33	Azerad MA, Bayoudh F, Weber T, Minon JM, Ketelslegers O, Hoyoux M, Ren X, Azerad MA, Bayoudh F, Weber T, et al: Sickle cell disease and COVID-19: Atypical presentations and favorable outcomes. eJHaem. 1:338–341. 2020.PubMed/NCBI View Article : Google Scholar
34	Singh A, Brandow AM and Panepinto JA: COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals. Blood Adv. 5:1915–1921. 2021.PubMed/NCBI View Article : Google Scholar
35	Alkindi S, Elsadek RA, Al-Madhani A, Al-Musalhi M, AlKindi SY, Al-Khadouri G, Al Rawahi B, Al-Ruqeishi S, Al-Yazeedi J, Wali YA, et al: Impact of COVID-19 on vasooclusive crisis in patients with sickle cell anaemia. Int J Infect Dis. 106:128–133. 2021.PubMed/NCBI View Article : Google Scholar
36	Gladwin MT: Cardiovascular complications in patients with sickle cell disease. Hematology Am Soc Hematol Educ Program. 2017:423–430. 2017.PubMed/NCBI View Article : Google Scholar
37	Rees DC, Williams TN and Gladwin MT: Sickle-cell disease. Lancet. 376:2018–2031. 2010.PubMed/NCBI View Article : Google Scholar
38	Piel FB, Steinberg MH and Rees DC: Sickle cell disease. N Engl J Med. 376:1561–1573. 2017.PubMed/NCBI View Article : Google Scholar
39	Petito E, Falcinelli E, Paliani U, Cesari E, Vaudo G, Sebastiano M, Cerotto V, Guglielmini G, Gori F, Malvestiti M, et al: Association of neutrophil activation, more than platelet activation, with thrombotic complications in coronavirus disease 2019. J Infect Dis. 223:933–944. 2021.PubMed/NCBI View Article : Google Scholar
40	Vingert B, Tamagne M, Desmarets M, Pakdaman S, Elayeb R, Habibi A, Bernaudin F, Galacteros F, Bierling P, Noizat-Pirenne F and Cohen JL: Partial dysfunction of Treg activation in sickle cell disease. Am J Hematol. 89:261–266. 2014.PubMed/NCBI View Article : Google Scholar
41	Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W and Tian DS: Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 71:762–768. 2020.PubMed/NCBI View Article : Google Scholar
42	Chakravorty S, Padmore-Payne G, Ike F, Tshibangu V, Graham C, Rees D and Stuart-Smith S: COVID-19 in patients with sickle cell disease-a case series from a UK tertiary hospital. Haematologica. 105:2691–2693. 2020.PubMed/NCBI View Article : Google Scholar
43	Raveendran AV, Jayadevan R and Sashidharan S: Long COVID: An overview. Diabetes Metab Syndr. 15:869–875. 2021.PubMed/NCBI View Article : Google Scholar
44	Zhang NH, Cheng YC, Luo R, Zhang CX, Ge SW and Xu G: Recovery of new-onset kidney disease in COVID-19 patients discharged from hospital. BMC Infect Dis. 21(397)2021.PubMed/NCBI View Article : Google Scholar
45	Townsend L, Fogarty H, Dyer A, Martin-Loeches I, Bannan C, Nadarajan P, Bergin C, O'Farrelly C, Conlon N, Bourke NM, et al: Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response. J Thromb Haemost. 19:1064–1070. 2021.PubMed/NCBI View Article : Google Scholar
46	Galeotti C and Bayry J: Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol. 16:413–414. 2020.PubMed/NCBI View Article : Google Scholar
47	Jurado RL: Iron, infections, and anemia of inflammation. Clin Infect Dis. 25:888–895. 1997.PubMed/NCBI View Article : Google Scholar
48	Demir NA, Basturk A, Ural O, Sumer S, Erdogdu B, Kiratli HE, Celik JB, Koplay M and Vatansev H: A case of Evans syndrome secondary to COVID-19. Blood Transfus. 19:85–88. 2021.PubMed/NCBI View Article : Google Scholar
49	Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, et al: Clinical and immunologic features in severe and moderate forms of coronavirus disease 2019. medRxiv: Feb 19, 2020 (Epub ahead of print). doi: 10.1101/2020.02.16.20023903.
50	Dar J, Mughal I, Hassan H, Al Mekki TE, Chapunduka Z and Hassan ISA: Raised D-dimer levels in acute sickle cell crisis and their correlation with chest X-ray abnormalities. Ger Med Sci. 8(Doc25)2010.PubMed/NCBI View Article : Google Scholar
51	Kubánková M, Hohberger B, Hoffmanns J, Fürst J, Herrmann M, Guck J and Kräter M: Physical phenotype of blood cells is altered in COVID-19. bioRxiv: 2021.02.12.429482, 2021.